What's new? Log in Free sign up

Intellia Therapeutics (NTLA) News and press releases

Company Profile

News

From Benzinga Pro

Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

Bernstein Initiates Coverage On Intellia Therapeutics with Outperform Rating, Announces Price Target of $54

News, Price Target, Initiation, Analyst Ratings

Bernstein analyst William Pickering initiates coverage on Intellia Therapeutics (NASDAQ:NTLA) with a Outperform rating and announces Price Target of $54.

Benzinga's Top Ratings Upgrades, Downgrades For March 14, 2023

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

Analyst Ratings for Intellia Therapeutics

Analyst Ratings

BMO Capital Upgrades Intellia Therapeutics to Outperform, Raises Price Target to $57

News, Upgrades, Price Target, Analyst Ratings

BMO Capital analyst Kostas Biliouris upgrades Intellia Therapeutics (NASDAQ:NTLA) from Market Perform to Outperform and raises the price target from $54 to $57.

Why Is Intellia Therapeutics Stock Trading Higher Today?

Intellia Therapeutics (NASDAQ: NTLA) shares are trading higher on Thursday after the company announced that the FDA cleared its Investigational New Drug application for NTLA-2002 for the treatment of hereditary angioedema.

Intellia Therapeutics Earnings Perspective: Return On Capital Employed

Chardan Capital Maintains Buy on Intellia Therapeutics, Lowers Price Target to $111

News, Price Target, Analyst Ratings

Chardan Capital analyst Geulah Livshits maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and lowers the price target from $129 to $111.

Credit Suisse Maintains Outperform on Intellia Therapeutics, Lowers Price Target to $76

News, Price Target, Analyst Ratings

Credit Suisse analyst Richard Law maintains Intellia Therapeutics (NASDAQ:NTLA) with a Outperform and lowers the price target from $88 to $76.

Oppenheimer Maintains Outperform on Intellia Therapeutics, Lowers Price Target to $93

News, Price Target, Analyst Ratings

Oppenheimer analyst Jay Olson maintains Intellia Therapeutics (NASDAQ:NTLA) with a Outperform and lowers the price target from $115 to $93.

Baird Maintains Neutral on Intellia Therapeutics, Lowers Price Target to $42

News, Price Target, Analyst Ratings

Baird analyst Jack Allen maintains Intellia Therapeutics (NASDAQ:NTLA) with a Neutral and lowers the price target from $58 to $42.

EF Hutton Maintains Buy on Intellia Therapeutics, Lowers Price Target to $116

News, Price Target, Analyst Ratings

EF Hutton analyst Michael King maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and lowers the price target from $123 to $116.

Raymond James Maintains Outperform on Intellia Therapeutics, Lowers Price Target to $94

News, Price Target, Analyst Ratings

Raymond James analyst Steven Seedhouse maintains Intellia Therapeutics (NASDAQ:NTLA) with a Outperform and lowers the price target from $124 to $94.

Intellia Therapeutics Q4 EPS $(1.40) Misses $(1.39) Estimate, Sales $13.57M Beat $11.33M Estimate

Intellia Therapeutics (NASDAQ:NTLA) reported quarterly losses of $(1.40) per share which missed the analyst consensus estimate of $(1.39) by 0.72 percent. This is a 28.44 percent decrease over losses of $(1.09) per share

Earnings Scheduled For February 23, 2023

Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.

Analyst Initiates Coverage On This Peer Lagging Gene-Editing Stock

Analyst Color, Biotech, News, Health Care, Price Target, Initiation, Small Cap, Analyst Ratings, General

Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2023

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

Cantor Fitzgerald Initiates Coverage On Intellia Therapeutics with Overweight Rating, Announces Price Target of $67

News, Price Target, Initiation, Analyst Ratings

Cantor Fitzgerald analyst Rick Bienkowski initiates coverage on Intellia Therapeutics (NASDAQ:NTLA) with a Overweight rating and announces Price Target of $67.

Expert Ratings for Intellia Therapeutics

Analyst Ratings

Benzinga's Top Ratings Upgrades, Downgrades For January 24, 2023

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

Press releases

From Benzinga Pro

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to NTLA-2002 for the Treatment of Hereditary Angioedema

Health Care, Press Releases

CAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Company Progress

Earnings, Press Releases

Initiated the global Phase 2 study of NTLA-2002, a CRISPR-based, potential single-dose treatment for hereditary angioedema (HAE)Submitted IND application for NTLA-2002 to enable patient enrollment in the U.S. for the

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2022 Earnings and Company Updates

News, Press Releases

CAMBRIDGE, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging

Intellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary Angioedema

Health Care, Press Releases, General

Innovation Passport provides entry to the U.K.'s Innovative Licensing and Access Pathway (ILAP), which aims to accelerate time to market and facilitate patient access to innovative medicines NTLA-2002 is a single-dose

Intellia Therapeutics Highlights Strategic Priorities and Anticipated 2023 Key Milestones

Strategic priorities focus on late-stage development of its CRISPR-based medicines while continuing to expand and validate its industry-leading genome editing platformSubmit IND application in mid-2023 as part of a

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.